Tom H. Greene, PhD

Chief, Division of Biostatistics


  • English

Academic Information

  • Departments: Family & Preventive Medicine - Adjunct Professor, Internal Medicine - Professor, Population Health Sciences - Professor
  • Divisions: Biostatistics, Epidemiology, Public Health

Academic Bio

Dr. Tom Greene is chief of the Division of Biostatistics in the Department of Population Health Sciences, and a Professor in the Division of Epidemiology of the Department of Internal Medicine. He is also Director of the Population Health Research Foundation in the Utah Center for Clinical and Translational Science, and currently holds an H.A. and Edna Benning Endowed Chair. Dr. Greene received his PhD in Statistics from Cornell University in 1985, and worked as an Assistant Professor in the Department of Statistics at the University of Kentucky from 1985 to 1989. He then served as a statistician at Case Western University and the Cleveland Clinic Foundation from 1989 through 2006, where he was the lead statistician on a substantial number of multi-center clinical trials, primarily in the field of Nephrology. Dr. Greene was the acting head of the Cleveland Clinic’s Cancer Biostatistics Core for 2 years from 1991-1993. Dr. Greene moved to the University of Utah in 2006, where he founded the Study Design and Biostatistics Center and subsequently the Population Health Research Foundation.

Dr. Greene serves as the lead statistician on many research projects in collaboration with clinical and translational investigators across the University of Utah and elsewhere, and carries out methodological research in the areas of clinical trial design, causal inference, and validation of surrogate endpoints. Dr. Greene is also a member of the Cancer Biostatistics Resource, and is involved in the design and analysis of a sequential, multiple assignment, randomized trial to promote smoking cessation. He is particularly interested in the problem of integrating information from multiple surrogate and clinical endpoints to evaluate treatment efficacy in randomized clinical trials.

Education History

Type School Degree
Doctoral Training Cornell University
Statistics/ Mathematics and Operation Research Minor
Graduate Training Cornell University
Undergraduate University of Kentucky
Mathematics and Psychology

Selected Publications

Journal Article

  1. Zheutlin AR, Mondesir FL, Derington CG, King JB, Zhang C, Cohen JB, Berlowitz DR, Anstey DE, Cushman WC, Greene TH, Ogedegbe O, Bress AP (2022). Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open, 5(1), e2143001.
  2. Delaney RK, Pinto NM, Ozanne EM, Stark LA, Pershing ML, Thorpe A, Witteman HO, Thokala P, Lambert LM, Hansen LM, Greene TH, Fagerlin A (2021). Study protocol for a randomised clinical trial of a decision aid and values clarification method for parents of a fetus or neonate diagnosed with a life-threatening congenital heart defect. BMJ Open, 11(12), e055455.
  3. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutirrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS, Chronic Kidney Disease Epidemiology Collaboration (2021). New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med.
  4. Heerspink HJ, Cherney D, Postmus D, Stefnsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJ, Correa-Rotter R, Rossing P, Sjstrm CD, Toto RD, Wheeler DC, DAPA-CKD trial committees and investigators (2021). A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int.
  5. Inker LA, Heerspink HJL, Tighiouart H, Chaudhari J, Miao S, Diva U, Mercer A, Appel GB, Donadio JV, Floege J, Li PKT, Maes BD, Locatelli F, Praga M, Schena FP, Levey AS, Greene T (2021). Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. Am J Kidney Dis, 78(3), 340-349.e1.
  6. Heerspink HJL, Stack AG, Terkeltaub R, Greene TA, Inker LA, Bjursell M, Perl S, Rikte T, Erlandsson F, Perkovic V, SAPPHIRE investigators (2021). Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrol Dial Transplant.
  7. Lane E, Magel JS, Thackeray A, Greene T, Fino NF, Puentedura EJ, Louw A, Maddox D, Fritz JM (2021). Effectiveness of training physical therapists in pain neuroscience education for patients with chronic spine pain: cluster-randomized trial. Pain.
  8. Wohlfahrt P, Nativi-Nicolau J, Zhang M, Selzman CH, Greene T, Conte J, Biber JE, Hess R, Mondesir FL, Wever-Pinzon O, Drakos SG, Gilbert EM, Kemeyou L, LaSalle B, Steinberg BA, Shah RU, Fang JC, Spertus JA, Stehlik J (2022). Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction. JAMA Cardiol, 6(8), 957-962.
  9. Steinberg BA, Zhang M, Bensch J, Lyons A, Bunch TJ, Piccini JP, Siu A, Spertus JA, Stehlik J, Wohlfahrt P, Greene T, Hess R, Fang JC (2021). Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. J Card Fail.
  10. Jones BE, Ying J, Nevers M, Alba PR, He T, Patterson OV, Jones MM, Stevens V, Shen J, Humpherys J, Peterson KS, Rutter ED, Gundlapalli AV, Weir CR, Dean NC, Fine MJ, Samore MC, Greene TH (2021). Computerized Mortality Prediction for Community-acquired Pneumonia at 117 Veterans Affairs Medical Centers. Ann Am Thorac Soc, 18(7), 1175-1184.
  11. Fritz JM, Lane E, McFadden M, Brennan G, Magel JS, Thackeray A, Minick K, Meier W, Greene T (2020). Physical Therapy Referral From Primary Care for Acute Back Pain With Sciatica : A Randomized Controlled Trial. Ann Intern Med, 174(1), 8-17.
  12. Fritz JM, Rhon DI, Teyhen DS, Kean J, Vanneman ME, Garland EL, Lee IE, Thorp RE, Greene TH (2020). A Sequential Multiple-Assignment Randomized Trial (SMART) for Stepped Care Management of Low Back Pain in the Military Health System: A Trial Protocol. Pain Med, 21(Suppl 2), S73-S82.
  13. Edmonston DL, Roe MT, Block G, Conway PT, Dember LM, DiBattiste PM, Greene T, Hariri A, Inker LA, Isakova T, Montez-Rath ME, Nkulikiyinka R, Polidori D, Roessig L, Tangri N, Wyatt C, Chertow GM, Wolf M (2020). Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. Am J Kidney Dis, 76(6), 842-850.
  14. Oshima M, Neuen BL, Li J, Perkovic V, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Mahaffey KW, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Jardine MJ, Heerspink HJL (2020). Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. J Am Soc Nephrol, 31(12), 2925-2936.
  15. Zenger B, Zhang M, Lyons A, Bunch TJ, Fang JC, Freedman RA, Navaravong L, Piccini JP, Ranjan R, Spertus JA, Stehlik J, Turner JL, Greene T, Hess R, Steinberg BA (2020). Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. J Cardiovasc Electrophysiol, 31(12), 3187-3195.
  16. Xu Y, Greene TH, Bress AP, Sauer BC, Bellows BK, Zhang Y, Weintraub WS, Moran AE, Shen J (2020). Estimating the optimal individualized treatment rule from a cost-effectiveness perspective. Biometrics.
  17. Brown SM, Peltan I, Kumar N, Leither L, Webb BJ, Starr N, Grissom CK, Buckel WR, Srivastava R, Butler AM, Groat D, Haaland B, Ying J, Harris E, Johnson S, Paine R 3rd, Greene T (2020). Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. Ann Am Thorac Soc.
  18. Akhlaghi N, Needham DM, Bose S, Banner-Goodspeed VM, Beesley SJ, Dinglas VD, Groat D, Greene T, Hopkins RO, Jackson J, Mir-Kasimov M, Sevin CM, Wilson E, Brown SM (2020). Evaluating the association between unmet healthcare needs and subsequent clinical outcomes: protocol for the Addressing Post-Intensive Care Syndrome-01 (APICS-01) multicentre cohort study. BMJ Open, 10(10), e040830.
  19. Brintz BJ, Howard JI, Haaland B, Platts-Mills JA, Greene T, Levine AC, Nelson EJ, Pavia AT, Kotloff KL, Leung DT (2020). Clinical predictors for etiology of acute diarrhea in children in resource-limited settings. PLoS Negl Trop Dis, 14(10), e0008677.
  20. Heerspink HJL, Stefnsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjstrm CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020). Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 383(15), 1436-1446.
  21. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Grriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjstrm CD, Langkilde AM, Heerspink HJL (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant, 35(10), 1700-1711.
  22. Coon ER, Destino LA, Greene TH, Vukin E, Stoddard G, Schroeder AR (2020). Comparison of As-Needed and Scheduled Posthospitalization Follow-up for Children Hospitalized for Bronchiolitis: The Bronchiolitis Follow-up Intervention Trial (BeneFIT) Randomized Clinical Trial. JAMA Pediatr, 174(9), e201937.
  23. Johnson JT, Sullivan KL, Nelson RE, Sheng X, Greene TH, Bailly DK, Eckhauser AW, Marino BS, Minich LL, Pinto NM (2020). Factors That Contribute to Cost Differences Based on ICU of Admission in Neonates Undergoing Congenital Heart Surgery: A Novel Decomposition Analysis. Pediatr Crit Care Med, 21(9), e842-e847.
  24. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, Ambrosius W, Chertow GM, Beddhu S (2020). The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. Diabetes Care, 43(8), 1878-1884.
  25. Brown SM, Peltan ID, Webb B, Kumar N, Starr N, Grissom C, Buckel WR, Srivastava R, Harris ES, Leither LM, Johnson SA, Paine R 3rd, Greene T (2020). Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. Ann Am Thorac Soc, 17(8), 1008-1015.
  26. Skolasky RL, Wegener ST, Aaron RV, Ephraim P, Brennan G, Greene T, Lane E, Minick K, Hanley AW, Garland EL, Fritz JM (2020). The OPTIMIZE study: protocol of a pragmatic sequential multiple assessment randomized trial of nonpharmacologic treatment for chronic, nonspecific low back pain. BMC Musculoskelet Disord, 21(1), 293.
  27. Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V, CREDENCE Study Investigators (2019). Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol, 31(5), 1128-1139.
  28. Jones BE, Ying J, Stevens V, Haroldsen C, He T, Nevers M, Christensen MA, Nelson RE, Stoddard GJ, Sauer BC, Yarbrough PM, Jones MM, Goetz MB, Greene T, Samore MH (2020). Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA Intern Med, 180(4), 552-560.
  29. Staub J, Siddiqui A, Murphy M, Lam R, Parikh M, Pleskow D, Papachristou G, Sharaiha R, Iqbal U, Loren D, Kowalski T, Noor A, Mumtaz T, Yasuda I, Thomas S, Hsaeeb A, Herrick J, Greene T, Adler DG (2020). Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study. Ann Gastroenterol, 33(2), 202-209.
  30. Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, Beddhu S (2020). Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial. Clin J Am Soc Nephrol, 15(2), 200-208.
  31. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigators (2019). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant, 35(2), 274-282.
  32. Fernandez ME, Schlechter CR, Del Fiol G, Gibson B, Kawamoto K, Siaperas T, Pruhs A, Greene T, Nahum-Shani I, Schulthies S, Nelson M, Bohner C, Kramer H, Borbolla D, Austin S, Weir C, Walker TW, Lam CY, Wetter DW (2020). QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers. Implement Sci, 15(1), 9.
  33. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K (2019). Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis, 75(1), 84-104.
  34. Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA (2019). Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol, 16(1), 51-64.
  35. Torrecillas V, Allen CM, Greene T, Park A, Chung W, Lanzieri TM, Demmler-Harrison G (2019). Should You Follow the Better-Hearing Ear for Congenital Cytomegalovirus Infection and Isolated Sensorineural Hearing Loss? Otolaryngol Head Neck Surg, 162(1), 114-120.
  36. Nkoy FL, Wilkins VL, Fassl BA, Johnson JM, Uchida DA, Poll JB, Greene TH, Koopmeiners KJ, Reynolds CC, Valentine KJ, Savitz LA, Maloney CG, Stone BL (2019). Contextual Factors Influencing Implementation of Evidence-Based Care for Children Hospitalized With Asthma. Hosp Pediatr, 9(12), 949-957.
  37. Rathi N, Whelton PK, Chertow GM, Cushman WC, Cheung AK, Wei G, Boucher R, Kimmel PL, Bress AP, Kramer HJ, Al-Marji C, Greene T, Beddhu S (2019). Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. Am J Hypertens, 32(12), 1170-1177.
  38. Vonesh E, Tighiouart H, Ying J, Heerspink HL, Lewis J, Staplin N, Inker L, Greene T (2019). Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat Med, 38(22), 4218-4239.
  39. Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T (2019). GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol, 30(9), 1735-1745.
  40. Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA (2019). Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. J Am Soc Nephrol, 30(9), 1756-1769.
  41. Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC (2019). An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney Int, 96(3), 750-760.
  42. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, Canfield RL, Dietrich KN, Bornschein R, Greene T, Rothenberg SJ, Needleman HL, Schnaas L, Wasserman G, Graziano J, Roberts R (2019). Erratum: "Low-Level Environmental Lead Exposure and Children's Intellectual Function: An International Pooled Analysis". Environ Health Perspect, 127(9), 99001.
  43. Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V (2019). Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 140(9), 739-750.
  44. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T (2019). Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. J Am Soc Nephrol, 30(8), 1523-1533.
  45. Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB, SPRINT Research Group (2019). Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension, HYPERTENSIONAHA11912907.
  46. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 380(24), 2295-2306.
  47. Nkoy FL, Fassl BA, Wilkins VL, Johnson J, Unsicker EH, Koopmeiners KJ, Jensen A, Frazier M, Gaddis J, Malmgren L, Williams S, Oldroyd H, Greene T, Sheng X, Uchida DA, Maloney CG, Stone BL (2019). Ambulatory Management of Childhood Asthma Using a Novel Self-management Application. Pediatrics, 143(6).
  48. Hammers DB, Foster NL, Hoffman JM, Greene TH, Duff K (2019). Neuropsychological, Psychiatric, and Functional Correlates of Clinical Trial Enrollment. J Prev Alzheimers Dis, 6(4), 242-247.
  49. Zuk A, Palevsky PM, Fried L, Harrell FE Jr, Khan S, McKay DB, Devey L, Chawla L, de Caestecker M, Kaufman JS, Thompson BT, Agarwal A, Greene T, Okusa MD, Bonventre JV, Dember LM, Liu KD, Humphreys BD, Gossett D, Xie Y, Norton JM, Kimmel PL, Star RA (2018). Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop. Clin J Am Soc Nephrol, 13(7), 1113-1123.
  50. Li L, Luo S, Hu B, Greene T (2017). Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease. Stat Biosci, 9(2), 357-378.
  51. Gallicchio L, Miller SR, Kiefer J, Greene T, Zacur HA, Flaws JA (2015). The Associations Between Body Mass Index, Smoking, and Alcohol Intake with Ovarian Volume in Midlife Women. J Womens Health (Larchmt), 25(4), 409-15.
  52. Beckmann JT, Wylie JD, Potter MQ, Maak TG, Greene TH, Aoki SK (2015). Effect of Naproxen Prophylaxis on Heterotopic Ossification Following Hip Arthroscopy: A Double-Blind Randomized Placebo-Controlled Trial. J Bone Joint Surg Am, 97(24), 2032-7.
  53. Thomas A, Redd A, Khader K, Leecaster M, Greene T, Samore M (2015). Efficient parameter estimation for models of healthcare-associated pathogen transmission in discrete and continuous time. Math Med Biol, 32(1), 79-98.
  54. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J (2014). GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis, 64(6), 821-35.
  55. Khader K, Leecaster M, Greene T, Samore M, Thomas A (2014). Improved hidden Markov model for nosocomial infections. Math Med Biol, 31(4), 338-52.
  56. Jones M, Ying J, Huttner B, Evans M, Maw M, Nielson C, Rubin MA, Greene T, Samore MH (2014). Relationships between the importation, transmission, and nosocomial infections of methicillin-resistant Staphylococcus aureus: an observational study of 112 Veterans Affairs Medical Centers. Clin Infect Dis, 58(1), 32-9.
  57. Greene T, Joffe M, Hu B, Li L, Boucher K (2013). The balanced survivor average causal effect. Int J Biostat, 9(2), 291-306.
  58. Jones M, Ying J, Huttner B, Evans M, Maw M, Nielson C, Rubin MA, Greene T, Samore MH (2013). Relationships Between the Importation, Transmission, and Nosocomial Infections of Methicillin-Resistant Staphylococcus aureus: An Observational Study of 112 Veterans Affairs Medical Centers. Clin Infect Dis.
  59. Hu B, Li L, Wang X, Greene T (2012). Nonparametric multistate representations of survival and longitudinal data with measurement error. Stat Med, 31(21), 2303-17.
  60. Mayer J, Greene T, Howell J, Ying J, Rubin MA, Trick WE, Samore MH, CDC Prevention Epicenters Program (2012). Agreement in classifying bloodstream infections among multiple reviewers conducting surveillance. Clin Infect Dis, 55(3), 364-70.
  61. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I, Collaborative Study Group (2011). Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis, 58(5), 729-36.
  62. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Investigators (2011). FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol, 22(10), 1913-22.
  63. Yan G, Greene T (2011). Statistical analysis and design for estimating accuracy in clinical-center classification of cause-specific clinical events in clinical trials. Clin Trials, 8(5), 571-80.
  64. Leecaster M, Gesteland P, Greene T, Walton N, Gundlapalli A, Rolfs R, Byington C, Samore M (2011). Modeling the variations in pediatric respiratory syncytial virus seasonal epidemics. BMC Infect Dis, 11, 105.
  65. Kevin Rogers R, Stehlik J, Stoddard GJ, Greene T, Collins SP, Peacock WF, Maisel AD, Clopton P, Michaels AD (2009). Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT. Eur J Heart Fail, 11(11), 1043-9.
  66. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA, African American Study of Hypertension and Kidney Disease Collaborative Research Group (2009). Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med, 169(17), 1587-94.
  67. Joffe MM, Greene T (2008). Related causal frameworks for surrogate outcomes. Biometrics, 65(2), 530-8.
  68. Greene T, Daugirdas JT, Depner TA, Gotch F, Kuhlman M, Frequent Hemodialysis Network Study Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (2009). Solute clearances and fluid removal in the frequent hemodialysis network trials. Am J Kidney Dis, 53(5), 835-44.
  69. Rubin MA, Mayer J, Greene T, Sauer BC, Hota B, Trick W, Jernigan JA, Samore MH (2008). An agent-based model for evaluating surveillance methods for catheter-related bloodstream infection. AMIA Annu Symp Proc, 631-5.
  70. Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY, African American Study of Kidney Disease and Hypertension Collaborative Research Group (2008). Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med, 168(8), 832-9.
  71. Garg AX, Greene T, Levin NW (2007). A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. Nephrol Dial Transplant, 23(1), 52-5.
  72. Samore MH, Shen S, Greene T, Stoddard G, Sauer B, Shinogle J, Nebeker J, Harbarth S (2007). A simulation-based evaluation of methods to estimate the impact of an adverse event on hospital length of stay. Med Care, 45(10 Supl 2), S108-15.
  73. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration (2007). Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem, 53(4), 766-72.
  74. Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Kliger AS, Frequent Hemodialysis Network Trial Group (2006). Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int, 71(4), 349-59.
  75. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J, AASK Study Group (2006). Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis, 48(5), 739-51.
  76. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ (2006). Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol, 17(9), 2599-606.
  77. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration (2006). Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med, 145(4), 247-54.
  78. Stevens LA, Greene T, Levey AS (2006). Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol, 1(4), 874-84.
  79. Stevens LA, Coresh J, Greene T, Levey AS (2006). Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med, 354(23), 2473-83.
  80. Lash JP, Wang X, Greene T, Gadegbeku CA, Hall Y, Jones K, Kusek JW, Sika M, Unruh M, African American Study of Kidney Disease and Hypertension Trial Study Group (2006). Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. Am J Kidney Dis, 47(6), 956-64.
  81. Menon V, Sarnak MJ, Greene T, Wang X, Pereira AA, Beck GJ, Kusek JW, Selhub J, Collins AJ, Levey AS, Shlipak MG (2006). Relationship between homocysteine and mortality in chronic kidney disease. Circulation, 113(12), 1572-7.
  82. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL (2005). The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med, 165(8), 947-53.
  83. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM (2004). Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol, 16(2), 459-66.
  84. Ogiste JS, Nejat RJ, Rashid HH, Greene T, Gupta M (2003). The role of mannitol in alleviating renal injury during extracorporeal shock wave lithotripsy. J Urol, 169(3), 875-7.
  85. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis HEMO Study Group (2002). Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med, 347(25), 2010-9.
  86. Greene T (2001). A model for a proportional treatment effect on disease progression. Biometrics, 57(2), 354-60.
  87. Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, Breyer JA, Faubert P, Rolin HA, Wang SR (1997). Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension, 30(3 Pt 1), 428-35.
  88. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM (1993). Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol, 4(5), 1159-71.
  89. Iglesias AA, Barry GF, Meyer C, Bloksberg L, Nakata PA, Greene T, Laughlin MJ, Okita TW, Kishore GM, Preiss J (1993). Expression of the potato tuber ADP-glucose pyrophosphorylase in Escherichia coli. J Biol Chem, 268(2), 1081-6.
  90. Greene T, Ernhart CB (1991). Adjustment for cofactors in pediatric research. J Dev Behav Pediatr, 12(6), 378-85.
  91. Ernhart CB, Greene T (1990). Low-level lead exposure in the prenatal and early preschool periods: language development. Arch Environ Health, 45(6), 342-54.


  1. Li L, Yang W, Astor BC, Greene T (2019). Competing Risk Modeling: Time to Put it in Our Standard Analytical Toolbox. J Am Soc Nephrol, 30(12), 2284-2286.
  2. Greene T, Li L (2017). From Static to Dynamic Risk Prediction: Time Is Everything. Am J Kidney Dis, 69(4), 492-494.
  3. Cheung AK, Greene T (2009). Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol, 20(3), 462-4.


  1. Presson AP, Greene TH, Ou Z, Zhang C, Tyser AR, Kazmers NH (2021). Reply to "The Problem of Collinearity in Mental Health and Patient Reported Outcome Research". [Letter to the editor]. J Hand Surg Am, 46(2), e3-e6.
  2. Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW (2019). Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. [Letter to the editor]. Circulation, 141(5), 407-410.
  3. Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA (2019). Strengths and limitations of estimated and measured GFR. [Letter to the editor]. Nat Rev Nephrol, 15(12), 784.
  4. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Greene T, Wei G, Boucher R, Whelton PK, SPRINT Research Group (2018). Response by Beddhu et al to Letters Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control". [Letter to the editor]. Circulation, 137(24), 2668-2669.
  5. Brown KA, Daneman N, Stevens V, Greene TH, Arora P (2016). Reply to Wolkewitz: When to Use Cumulative Risk-Based Versus Rate-Based Approaches in the Analysis of Hospital-Acquired Infection Risk Factors? That Depends on the Question. [Letter to the editor]. Infect Control Hosp Epidemiol, 37(9), 1124-5.
  6. Joseph JV, Greene T (2007). Re: Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% K. Touijer, F. Rabbani, J. R. Otero, F. P. Secin, J. A. Eastham, P. T. Scardino And B. Guillonneau J Urol 2007; 178: 120-124. [Letter to the editor]. J Urol, 179(2), 789-90.


  1. Jones, M, Rubin, M, Greene, T, Leecaster, M, Spuhl, J, Nielson, C, Evans, M, Jain, R, Samore, M (2011). Comparing the Performance of Clinical History of MRSA vs. Active Surveillance at Individual and Hospital Ward Levels [Abstract]. Infectious Disease Society of America Conference, Vancouver, British Columbia, Canada.
  2. Jones, M, Ying, J, Greene, T, Leecaster, M, Huttner, B, Mayer, J, Rubin, M, Samore, M (2011). Analysis of MRSA Transmission Dynamics in the Veterans Affairs System [Abstract]. Annual Scientific Meeting of The Society for Healthcare Epidemiology of America.
  3. Mayer J, Howell J, Weir CR, Rubin MA, Greene T, Samore MH (2011). Use of electronic reporting and annotations by Infection Preventionists to describe differences in the application of surveillance criteria. [Abstract]. Society for Healthcare Epidemiology of America.
  4. Mayer J, Howell J, Greene T, Rubin M, Ray W, Nordberg B, Hayden C, Nechodom P, Samore M (2010). Assessing inter-rater reliability of surveillance decisions by infection preventionists [Abstract]. Society for Healthcare Epidemiology of America.
  5. Lash JP, Gadegbeku C, Greene T, Hall Y, Jones K, Kusek JW, Sika M, Wang X for the AASK Study Group (2003). Longitudinal effects of blood pressure level and antihypertensive regimen on quality of life in the AASK Study. [Abstract]. Journal of the American Society of Nephrology, 14, 678A.
  6. Kusek JW, Agodoa L, Greene T, Jones C (1993). Modification of Diet in Renal Disease (MDRD) Study Group.Comparison of decline of GFR in Blacks versus Non-Blacks in the MDRD Study [Abstract]. Journal of the American Society of Nephrology, 4, 253.


  1. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One (16(4), pp. e0248080). United States.